Core Viewpoint - Zhongkang Holdings (02361) is upgrading its strategy from a "provider of intelligent solutions in the life sciences" to an "AI technology service company based on health industry data elements and ecological resources" [1] Group 1: Strategic Upgrade - The company is transitioning from "data technology services" to "AI decision-making and intelligent services," leveraging a comprehensive capability of "data + model + scenario + ecology" [1] - The dual-domain large model includes: (1) Zhuomuniao (medical large model), which is trained on medical literature, case histories, and pharmaceutical knowledge graphs, evaluated by medical experts for enhanced professionalism and accuracy; (2) Tiangong No. 1 (decision-making large model), which integrates diverse market data and industry logic with medical knowledge to create actionable marketing strategies and resource allocation plans [1] Group 2: Data Resources and Industry Insights - The company possesses a diverse range of health industry data resources covering medical institutions, health check-up centers, and pharmacies, establishing a comprehensive data system from hospitals to outpatient services, online to offline, and prevention to treatment [1] - With 18 years of industry know-how, the company decodes the business logic behind the data, dismantling complex business scenarios to assist in key decision-making [1] Group 3: AI Service System and Team Collaboration - The company has built a complete AI service system from foundational to front-end applications, capable of meeting diverse needs from SMEs to large corporate clients [2] - The team and partners combine top-tier AI technology with extensive pharmaceutical experience, ensuring the integration of technology with medical scenarios to create quantifiable value [2] - Under the new strategic guidance, Zhongkang will leverage its core capabilities to drive AI implementation across four key scenarios: health industry marketing, medical services, pharmacies, and health management [2] Group 4: Future Development - The company will adhere to its established development strategy, building an efficient collaborative ecosystem of health industry intelligent entities based on industrial-level data, continuously leading the industry into a new era of intelligence [3]

Core Viewpoint - The company is transitioning from a "provider of intelligent solutions in the life sciences" to an "AI technology service company based on health industry data elements and ecological resources" [1] Group 1: Strategic Upgrade - The strategic upgrade from "data technology services" to "AI decision-making and intelligent services" is based on a comprehensive capability of "data + model + scenario + ecology" [1] - The company is developing dual-domain large models: (1) Zhuo Mu Niao (medical large model) trained on medical literature, case histories, and pharmaceutical knowledge graphs, evaluated by medical experts for enhanced professionalism and accuracy; (2) Tian Gong Yi Hao (decision-making large model) integrates diverse market data and industry logic with medical knowledge to create marketing strategies and resource allocation plans [1] Group 2: Data Resources and Industry Insights - The company possesses a diverse range of health industry data resources covering medical institutions, health check-up centers, and pharmacies, creating a comprehensive data system from hospitals to outpatient services and from prevention to treatment [1] - With 18 years of industry know-how, the company decodes the business logic behind the data and dissects complex business scenarios to assist in key decision-making [1] Group 3: AI Service System and Team Collaboration - The company has established a complete AI service system from foundational to front-end applications, capable of meeting diverse needs from SMEs to large corporate clients [2] - The team and partners combine top-tier AI technology with extensive pharmaceutical experience, ensuring the integration of technology with medical scenarios to create quantifiable value [2] Group 4: Core Scenarios for AI Implementation - The company aims to drive industry transformation by leveraging its core capabilities in four key scenarios: health industry marketing, medical services, pharmacies, and health management [2] - In marketing, the company is launching commercial AI agents based on the "Tian Gong Yi Hao" decision model for more efficient marketing strategy generation [2] - In the medical sector, the focus will be on developing the "iMDT" intelligent agent for multidisciplinary consultations to enhance decision quality for doctors and hospitals [2] - For pharmacies, the company will enhance professional service capabilities across five dimensions: operational insights, products, diseases, membership, and staff to achieve intelligent management [2] - In health management, the company is committed to developing a comprehensive "prevention-screening-intervention" health management system through a matrix of intelligent agents [2] Group 5: Future Development - The company will adhere to its established development strategy, building an efficient collaborative ecosystem of health industry intelligent agents based on industrial-level data, leading the industry into a new era of intelligence [3]

中康控股戰略升級 本公告由中康控股有限公司（「本公司」或連同其附屬公司統稱「本集團」）自願作出，旨在向 本公司股東及潛在投資者更新本集團的最新業務發展情況。 一、戰略定位 本公司董事會欣然宣佈，於本公告日期，本公司戰略將由「生命科學領域數智化解決 方案提供商」，正式升級邁向「以健康產業數據要素和生態資源為基礎的AI科技服務公 司」。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 自願公告 公司構建了從基座到前端應用的 AI服務體系，基於多維度的服務模式，我們具備 服務從中小企業到集團客戶的多樣化需求的能力；我們的團隊及合作夥伴兼具頂 尖AI技術與資深醫藥經驗，我們將持續深度融合技術與醫療場景，確保產品的落 地並創造可量化價值。 三、業務規劃及落地場景 在公司最新戰略的指導下，中康將充分利用其核心能力，構建健康產業營銷、醫 ...